Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cost of Revenue (2016 - 2025)

Vanda Pharmaceuticals' Cost of Revenue history spans 12 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 47.99% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $13.0 million, up 15.29%, while the annual FY2025 figure was $13.0 million, 15.29% up from the prior year.
  • Cost of Revenue for Q4 2025 was $3.8 million at Vanda Pharmaceuticals, up from $3.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $6.8 million in Q3 2021 and bottomed at $2.6 million in Q3 2024.
  • The 5-year median for Cost of Revenue is $3.7 million (2025), against an average of $4.5 million.
  • The largest annual shift saw Cost of Revenue crashed 51.53% in 2023 before it soared 47.99% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $6.2 million in 2021, then grew by 0.03% to $6.2 million in 2022, then crashed by 44.53% to $3.5 million in 2023, then dropped by 25.14% to $2.6 million in 2024, then skyrocketed by 47.99% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cost of Revenue are $3.8 million (Q4 2025), $3.0 million (Q3 2025), and $2.7 million (Q2 2025).